Some of the hottest penny stocks to buy now are in the biotech sector. Start-ups and early phase biotechnology companies can provide explosive profit potential for investors who are in on the ground floor of a game-changing medical technology or blockbuster drug.
That said, finding hot penny stocks in the biotech sector is no easy task. There are lots of micro-caps and pink sheet stocks out there that wreak havoc on the portfolios of penny stock investors. But buying penny stocks doesn’t have to be an all-out gamble – by screening for investments with a decent market cap ($100 million or more) and listing on a major exchange, you can find ultra cheap stocks that are very fast movers but considerably less risk.
Here are my favorite four biotech penny stocks to buy now:
YM BioSciences Inc: The first stock on the list is biopharmaceutical company YM BioSciences Inc. (AMEX: YMI), which develops products for the treatment of cancer. In the last 12 months, YMI stock has gained +63%. More recently, YMI is up +8% year-to-date and is trading near its 52-week high of $2.52.
Dynavax Technologies: Known for discovering and developing products for the prevention and treatment of infectious diseases, asthma and autoimmune diseases, Dynavax Technologies (NASDAQ: DVAX) has gained +36% in the last six months. Going further back, this penny stock has shown impressive gains of +84% in the last year.
Zalicus Inc: Since the start of 2011, Zalicus Inc. (NASDAQ: ZLCS) has watched its stock value rise +44%, compared to much smaller gains by the broader markets. This biopharmaceutical company, which focuses on the treatment of pain and inflammation, has experienced stock growth of +70% since last April. Buy this stock with a 52-week range of $1.01 to $2.72. Zalicus is one of InvestorPlace.com’s 10 Best Stocks for 2011.
AEterna Zentaris Inc: Drug development company AEterna Zentaris Inc. (NASDAQ: AEZS) specializes in oncology and endocrine therapy. Since the start of 2011, this penny stock has raised its stock value of +8%. Investors are even more thrilled to see 52-week growth of +87%.
As of this writing, Louis Navellier did not own a position in any of the stocks named here.